SABR plus targeted therapy and immunotherapy for advanced kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests combining a precise type of radiation (SABR) with standard targeted therapy and immunotherapy drugs for kidney cancer that has come back or spread. The goal is to see if adding radiation improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have recurrent or metastatic kidney cancer that was confirmed by biopsy.
- You have at least one tumor that a doctor says can be treated with SABR radiation.
- You are planning to start or are already on first or second-line targeted therapy plus immunotherapy.
- You are 18 years or older and have a life expectancy of at least 12 weeks.
- Your overall health is good (ECOG score 0 or 1) and your heart, bone marrow, liver, and kidneys work well enough.
- You have not had cancer in the last 5 years (except some low-risk or cured cancers) and no uncontrolled medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (axitinib) and immunotherapy (toripalimab) alongside stereotactic body radiation therapy (SBRT) for kidney cancer that has come back or spread. It may be an option if you have a limited number of metastatic tumors that can be treated with radiation.
This trial uses two types of PET scans to better target radiation therapy in patients with advanced clear cell kidney cancer that has spread or returned. The goal is to combine radiation with standard drug treatments to improve outcomes.
This study tests whether a precise, high-dose radiation treatment (SABR) can safely control kidney cancer that has spread to a few spots in the body. It may be an option if your cancer is progressing during treatment and your spots can be safely targeted with radiation.
This trial tests whether combining focused radiation (SBRT) with anlotinib and bimepolizumab can shrink or slow kidney cancer that has spread and cannot be surgically removed. It's designed for people with a specific type of kidney cancer who are generally healthy enough to handle these treatments.
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
This trial studies whether combining a special type of radiation (SBRT) with an immunotherapy (PD-1 blocker) can shrink kidney cancer that has already spread. It is for people who have already had this combination treatment before.
Hear when a new Radiation Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.